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Abstract
Background: The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC. These mutations
can be targeted by RTK inhibitors (TKIs) such as erlotinib. Chromatin-modifying agents may offer a novel
therapeutic approach by sensitizing tumor cells to TKIs.
Methods: The NSCLC cell lines HCC827 (EGFR mutant, adenocarcinoma), A549 (EGFR wt, adenocarcinoma) and
NCI-H460 (EGFR wt, large cell carcinoma) were analyzed by SNP6.0 array. Changes in proliferation after panobinostat
(LBH-589, PS) and erlotinib treatment were quantified by WST-1 assay and apoptosis by Annexin V/7-AAD flow
cytometry. Abundance of target proteins and histone marks (acH3, H3K4me1/2/3) was determined by immunoblotting.
Results: As expected, the EGFR wt cell lines A549 and NCI-H460 were quite insensitive to the growth-inhibitory effect
of erlotinib (IC50 70-100 μM), compared to HCC827 (IC50 < 0.02 μM). All three cell lines were sensitive to PS treatment
(IC50: HCC827 10 nM, A549 20 nM and NCI-H460 35 nM). The combination of both drugs further reduced proliferation
in HCC827 and in A549, but not in NCI-H460. PS alone induced differentiation and expression of p21WAF1/CIP1 and p53
and decreased CHK1 in all three cell lines, with almost no further effect when combined with erlotinib. In contrast,
combination treatment additively decreased pEGFR, pERK and pAKT in A549. Both drugs synergistically induced acH3
in the adenocarcinoma lines. Surprisingly, we also observed induction of H3K4 methylation marks after erlotinib
treatment in HCC827 and in A549 that was further enhanced by combination with PS.
Conclusion: PS sensitized lung adenocarcinoma cells to the antiproliferative effects of erlotinib. In these cell lines,
the drug combination also had a robust, not previously described effect on histone H3 acetylation and H3K4
methylation.
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Background
Lung cancer remains the leading cause of cancer-related
death worldwide [1]. For stage IIIB/IV non-small cell
lung cancer (NSCLC) patients, the median survival with
standard chemotherapy is approximately 10 months [2].
While treatment with tyrosine kinase inhibitors (TKIs)
can dramatically prolong survival in a subgroup of pa-
tients, their therapeutic index depends heavily on the
patients’ Epidermal Growth Factor Receptor (EGFR) mu-
tational status [3]. While reversible first-generation TKIs
like erlotinib and gefitinib are superior to chemotherapy
in EGFR-mutated patients, they show less activity in pa-
tients with wildtype (wt) EGFR [4, 5]. Different attempts
have been undertaken to sensitize EGFR wt NSCLC cells
to the antineoplastic effects of TKIs, including combin-
ation therapy with epigenetically active drugs [6].
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Histone deacetylase inhibitors (HDACis) exert their
anticancer effects by increasing acetylation of core his-
tones as well as non-histone proteins, thereby influen-
cing gene transcription and ultimately leading to the
induction of apoptosis, differentiation or degradation of
misfolded proteins [7]. To date, three HDACis, vorino-
stat (SAHA), romidepsin and panobinostat (LBH-589,
PS), have been FDA-approved for the treatment of cuta-
neous and peripheral T-cell lymphoma and multiple
myeloma. In contrast, in solid tumors single-agent treat-
ment with HDACis exhibits only a limited clinical bene-
fit [8]. However, the combination with different cancer
therapeutics (chemo-, radio- or antihormonal therapy as
well as TKIs), has demonstrated increased efficacy in
several settings [9, 10].
HDACis and TKIs affect common downstream path-
ways: both alter the expression of cell cycle regulators
such as p21WAF1/CIP1, p53 or CHK1 [11, 12]. Downregu-
lation of CHK1 was recently shown to be a potential
pharmacodynamic biomarker for HDACi response in
NSCLC patients and was negatively correlated with the
expression of E-cadherin [13]. On the other hand, E-
Cadherin is also an important protein of interest, as its
loss leads to both metastatic spread and resistance to
TKI treatment, and it was already shown to be upregu-
lated by HDACi in vitro [14]. Thus, high E-Cadherin ex-
pression is not only a prognostic marker for a better
outcome in lung cancer but also correlates with response
to TKIs [14]. Non-toxic treatment regimens combining
HDACis and TKIs have been established [13, 15], and
first clinical trials showed that the combination therapy
is especially effective in patients expressing high E-
Cadherin levels [16].
Recent publications could also demonstrate a cross-
talk between HDACi induced histone acetylation and
histone methylation that resulted in differentiation
and induction of tumor suppressor genes, such as
p21WAF1/CIP1 [17, 18].
Here, we utilized three NSCLC cell lines with differ-
ent genotypes (regarding EGFR and KRAS mutational
status, different copy number gains and losses of genes
relevant for lung cancer) to investigate the molecular
mechanisms of the combination of the pan-HDACi PS
with erlotinib. In this study, we could show that the
combination of erlotinib with PS indeed exerts additive
antineoplastic effects upon the EGFR-mutated adeno-
carcinoma cell line HCC827 and the EGFR wt adeno-
carcinoma cell line A549, whereas this effect was not
seen in the large-cell carcinoma cell line NCI-H460.
Interestingly, the deposition of activating histone
marks mediated by HDACi treatment with PS, includ-
ing histone methylation marks, was enhanced by erlo-




Three non-small cell lung cancer lines HCC827, A549
and NCI-H460 (ATCC, American Type culture collection,
Manassas, VA; USA; DSMZ, Braunschweig, Germany)
with different histological properties as well as EGFR and
KRAS mutational status were cultured in RMPI 1640
(Gibco, Thermo Fisher Scientific Inc.) incl. 10 % FCS (Bio-
chrome, Merck Millipore, Berlin, Germany) and 100U/ml
penicillin/streptomycin (Gibco) at 37 °C and 5 % CO2.
HCC827 is an adenocarcinoma line with the E746 -
A750 EGFR deletion [19]. A549 is of the same histo-
logical NSCLC subtype and harbors a KRAS mutation,
but is EGFR wildtype [20]. NCI-H460 is a large-cell car-
cinoma line, also with mutated KRAS and wildtype
EGFR [21]. As published in the COSMIC database, none
of the three cell line harbors a TP53 mutation (http://
cancer.sanger.ac.uk/ cancergenome/projects/cosmic/).
Since we only used commercially available cell lines,
no approval of an appropriate ethics committee was
needed.
Treatment of cells, growth inhibition and measurement of
apoptosis
IC50 concentrations of panobinostat (LBH-589, PS, LC
laboratories, Woburn, MA, USA) and erlotinib (LC la-
boratories) were determined by WST-1 assay (Roche
Applied Science, Mannheim, Germany). Briefly, 5x102/
ml cells were seeded in 96-well plates, treated on three
consecutive days with different concentrations of PS or
erlotinib and changes in proliferation were measured ac-
cording to manufacturer’s protocol. IC50 values were
reached when cell growth was inhibited to 50 % of
the DMSO control. As previously described, the IC50
concentrations for PS were 10nM for HCC827, 20 nM
for A549 and 35 nM for NCI-H460 [22]. Since the
EGFR wt cells were highly insensitive to erlotinib a
dose of 2 μM was used. For treatment of EGFR
mutated HCC827 cells a non-toxic concentration of
10 nM erlotinib was used.
Both PS and erlotinib were dissolved in DMSO (Sigma)
in stock solution of 1 mM and 10 mM, respectively, and
diluted to the corresponding concentrations directly prior
to the treatment for each timepoint.
Cell death was observed by trypan blue exclusion assay
and by flow cytometry measurement with Annexin V
(eBioscience, Frankfurt a.M., Germany) and 7-AAD (BD
Pharmingen, Heidelberg, Germany) staining.
Western blot
After treatment with the corresponding IC50-dose of PS
and 2 μM (10 nM, respectively) erlotinib as single agents
and in combination, 5x106 NSCLC cells per condition
were harvested after 24, 48 and 72 h. DMSO as well as
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medium-only served as negative controls. Whole cell
lysis and protein isolation was performed according to
protocol (Active Motif ) and protein concentration was
measured by BCA assay (Thermo Scientific). Equal
amounts of protein were separated using 4-12 % gradi-
ent Bis/Tris acrylamide gels in the NuPAGE electrophor-
esis and blotting system (Invitrogen, Thermo Scientific).
Antibodies against phospho- and total ERK, phospho-
and total AKT, phospho-and total CHK1, β-catenin (Cell
Signaling Technology), E-cadherin (BD Transduction La-
boratories), acetylated histone H3, H3K4me1,–2,–3 (Merck
Millipore), p21WAF1/CIP1, p53, GAPDH, alpha-tubulin, and
HRP-labeled secondary antibodies against goat, rabbit and
mouse (Santa Cruz Biotechnology) were used. ECL Plus
Western Blotting Detection System (Thermo Scientific)
served as substrate for chemoluminescence.
SNP-array analysis
DNA was isolated from 5x106 cells per cell line accord-
ing to manual with the Blood & Tissue DNeasy Mini Kit
(Qiagen). DNA concentration was measured with Nano-
Drop1000 (Thermo Scientific).
500 ng of genomic DNA were used for SNP array ana-
lysis (Genome-Wide Human SNP Array 6.0 Affymetrix).
Copy number variations were analyzed with the Geno-




Statistical analysis of data was performed using the
GraphPad Prism 5.0 software with Student’s t-test to test
differences between two treatment groups and a linear
regression model for the identification of the corre-
sponding IC50 values.
Results
Characterization of three NSCLC cell lines reveals copy
number variations in oncogenes and tumor suppressor
genes
Before treatment of the cell lines HCC827, A549 and
NCI-H460, we wished to confirm and extend the genetic
information given by the provider. We analyzed copy
number (CN) variations by SNP array, since copy num-
ber amplifications of EGFR, MYC and KRAS and TP63
are often described in NSCLC. Specifically EGFR mu-
tated cells like HCC827 display an amplification of the
oncogene [23] which we could confirm (Table 1). Simi-
larly, amplification of MYC was validated for the NCI-
H460 cells (with a concomitant CN reduction of EGFR).
Amplifications of KRAS could be confirmed for A549
(KRAS mut) and the KRAS wt HCC287 [24]. None of
the three cell lines showed amplifications of MET, which
are closely linked to TKI resistance [25, 26]. No CN
gains or losses were detected for ALK, BRAF and PI3K,
(Table 1).
Panobinostat enhances the antiproliferative effect of
erlotinib in EGFR-mutant and -wildtype cell lines
We next examined growth-inhibitory effects of erlotinib
and PS, alone and in combination. NSCLC patients usu-
ally receive a daily dose of 150 mg erlotinib, which re-
sults in plasma levels between 1 and 3 μM [27]. Thus we
chose to treat the EGFR wildtype cells with an erlotinib
concentration of 2 μM. Additionally, we performed ex-
tensive dose-findings to determine the most effective but
also least toxic doses for PS in combination with erloti-
nib (Fig. 1a).
As expected, proliferation of A549 and NCl-H460 cells
was not inhibited by erlotinib alone, while EGFR mutant
HCC827 cells showed striking growth inhibition already
at 10 nM (Fig. 1b). Treatment with PS at nanomolar
doses impaired proliferation in all three cell lines, with
HCC827 being most sensitive [22]. When combining PS
and erlotinib, a time- and dose-dependent growth inhib-
ition could be observed, with a significantly additive
effect of PS across the entire dose range in HCC827 and
A549. In NCI-H460, erlotinib showed no additional
effect. (Fig. 1b). Inhibition of proliferation was not ac-
companied by an increase in cytotoxicity and apoptosis
(Fig. 2).
Combined panobinostat/erlotinib treatment reduces
phospho-EGFR
Binding of its ligands leads to EGFR dimerization and
autophosphorylation, allowing the recruitment of its
downstream targets. Therefore, phosphorylation is an in-
dicator for activated EGFR.
As shown in Fig. 3a, after 72 h PS slightly reduced
phospho-EGFR in both EGFR wt cell lines whereas no
Table 1 Copy number variations of oncogenes and tumor suppressors in three NSCLC cell lines
gene ALK BRAF CDKN1A EGFR KRAS MET MYC TP53 TP63 PI3K
HCC827 n n n 4 3 n 4 3 n n
A549 n n 1 3 3 n 3 n 1 n
NCI-H460 n n 1 1 n n 4 n n n
Copy numbers of selected genes in HCC827, A549 and NCI-H460 were determined by Affymetrix SNP Array 6.0
0 = complete loss, 1 = 50 % loss, n = no loss or gain, 3 = 50 % gain and 4 = 100 % gain of genomic material, relative to ploidy (all percentages are approximate
values computed with Affymetrix Genotyping Console Software)
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Fig. 1 a Combination dose-finding studies with panobinostat and erlotinib. The three NSCLC cell lines HCC827, A549 and NCI-H460 were treated
with three different concentrations of PS in combination with five concentrations of erlotinib to determine by WST-1 assay the most effective
combination dose that reduces proliferation to 50 % compared to the vehicle (DMSO) control after 72 h (representative experiment with
biological triplicates shown). The concentration ranges of both drugs were determined beforehand in independent experiments (data not shown).
b Combination treatment with panobinostat and erlotinib significantly reduces proliferation of NSCLC adenocarcinoma cell lines. Proliferation of
NSCLC cells after treatment with PS and/or erlotinib was measured by WST-1 assay after 24, 48 and 72 h, normalized to DMSO vehicle treated
cells. The combination of PS and erlotinib reduced proliferation significantly after 72 h in HCC827 and A549 cells (compared to PS alone; *** p < 0.001
Student’s t-test, paired, two-tailed)
Fig. 2 Combination treatment with panobinostat and erlotinib shows no increase in cytotoxicity after 72 h. Viability of NSCLC cells after 72 h of
treatment with PS and/or erlotinib measured via Trypan blue exclusion assay. No significant induction of cell death was measured. This was also
validated by flow cytometry with Annexin V and 7-AAD (data not shown)
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effect could be detected in HCC827. As expected, a re-
sponse to erlotinib could be seen in HCC827, but also
A549 showed a decrease in phospho-EGFR. Combining
the two compounds further downregulated phospho-
EGFR in HCC827, A549 and, to a lesser extent, also in
NCI-H460.
Panobinostat and erlotinib affect the expression of
downstream targets of the EGFR pathway
EGFR is located upstream of a signaling cascade that in-
cludes the PI3K/AKT- and RAS/MAPK-pathways and
regulates cell differentiation and proliferation. Western
Blot was performed to investigate the effects of erlotinib
± PS on the expression and phosphorylation of EGFR
downstream proteins AKT and ERK.
In HCC827, erlotinib diminished phospho-AKT almost
completely; this effect could not be further increased by
PS. Unexpectedly, single agent erlotinib was not only
unable to decrease the already low, phospho-ERK levels,
but rather induced phosphorylation of ERK. In A549, er-
lotinib had no effect on phospho-ERK but induced the
expression of phospho-AKT, whereas PS reduced phos-
phorylation of AKT and ERK. In NCI-H460, erlotinib had
no effect on phospho-AKT or phospho-ERK. PS alone
could only slightly reduce the phosphorylation of AKT,
but, in contrast, increased phosphorylation of ERK after
72 h. As in A549, no cooperative effect of the combination
could be detected (Fig. 3b).
In EGFR mutated cells, erlotinib counteracts panobinostat-
induced increase of p21 WAF1/CIP1 and p53 and decrease
of CHK1
The p53 pathway reacts to different stress signals caused
by e.g. DNA damage or hypoxia. Its downstream targets
include the CDK inhibitor p21WAF1/CIP1, which however
can also be induced p53-independently [28]. Both
Fig. 3 a Panobinostat and erlotinib cooperate in reducing the abundance of phospho-EGFR in NSCLC cell lines. Western Blot analysis of the
TKI-sensitive cell line HCC827 and the TKI-insensitive cell lines A549 and NCI-H460 was performed using antibodies against the phosphorylated
EGF-receptor and, serving as control, total EGFR. b Panobinostat and erlotinib differentially regulate phospho-AKT and phospho-ERK. Western blot
analysis of the proliferation and survival promoting proteins of the MAPK-pathway: phospho-ERK (compared to total ERK), and of the PI3K-
pathway: phospho-AKT (compared to total AKT). c Regulation of cell cycle proteins p21WAF1/CIP1, p53 and CHK1 by panobinostat and erlotinib
combination treatment. Western blot analysis after 24, 48 and 72 h of treatment with PS and/or erlotinib was performed using antibodies against
p21WAF1/CIP1, p53, phosphorylated CHK1 (Ser280) and total CHK1. An induction of p21WAF1/CIP1 and p53 after PS as well as combination treatment
was detectable in both EGFR wt cell lines A549 and NCI-H460 only. A downregulation of CHK1 after PS and combination treatment was seen in
all three cell lines. d Panobinostat alone and in combination with erlotinib upregulates E-Cadherin and β-catenin in the EGFR wildtype NSCLC
adenocarcinoma cell line A549. Western blot analysis of the three NSCLC lines after 24, 48 and 72 h of combination treatment was performed
using antibodies against E-Cadherin and β-Catenin
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cooperatively downregulate CHK1 [29]. Additionally,
AKT further inhibits CHK1 function by phosphorylation
of Ser280. As already shown, HDAC inhibition leads to
an upregulation of p21 WAF1/CIP1, acetylation and induc-
tion of p53 and reduction of CHK1 [12, 30].
In all three cell lines, PS led to a strong p21WAF1/CIP1
induction. Whereas in NCI-H460 p21WAF1/CIP1 was in-
creased even further by PS + erlotinib, in HCC827 the
combination antagonized this induction almost entirely.
In A549 combination treatment had almost no add-
itional effect (Fig. 3c). In the HCC827 cell line, erlotinib
led to a slight increase of p53 after 72 h, whereas with
PS or the combination of both drugs p53 levels were
modestly decreased. In A549 and NCI-H460, a marked
increase of p53 expression was only apparent after 72 h
of PS and combination treatment (no additive effect)
(Fig. 3c, middle and lower panel).
CHK1 decreased markedly in all three cell lines
after 72 h of HDACi treatment. In HCC827 and A549
add-on of erlotinib further enhanced this effect. In
line with the AKT immunoblot results, phospho-
CHK1 was slightly increased in all three cell lines
after erlotinib treatment.
The panobinostat and erlotinib combination induces an
epithelial phenotype in HCC827 and A549 cells
Epithelial to mesenchymal transition (EMT) plays a
major role in the metastatic behavior of NSCLC. Also,
loss of the epithelial marker E-cadherin is a hallmark in
the development of TKI resistance [14]. In HCC827, PS
modestly upregulated E-cadherin, indicative of some
EMT induction (Fig. 3d, upper panel), as did erlotinib
and the combination treatment (72 h). PS alone mod-
estly induced β-catenin expression, whereas the combin-
ation with erlotinib had the opposite effect (which
appeared to outweigh the effect of HDAC inhibition).
A549 did not disclose E-cadherin or β-catenin induction
by erlotinib, whereas PS, both alone and in combination
with erlotinib, led to an increased expression of both
proteins. NCI-H460 showed a different response: PS
alone and in combination with erlotinib reduced β-
catenin. (No E-cadherin expression was detectable in
this cell line, neither before nor after treatment, Fig. 3d,
lower panel) [22, 31].
Erlotinib enhances panobinostat-induced acetylation of
histone H3
As expected, PS robustly induced acetyl-histone H3
(acH3). Erlotinib had no effect on H3 acetylation, but it
enhanced the effect of PS on acH3 (in HCC827 and
A549). In NCI-H460, it modestly induced acH3 after
24 h, but the combination treatment did not lead to an
additive effect compared to PS alone (Fig. 4).
The combination of panobinostat and erlotinib leads to
synergistic induction of activating histone methylation
marks in HCC827 and A549
Others [32] as well as ourselves [33], could show that
HDAC inhibitors also exert an effect on different histone
methylation marks. Therefore we also investigated the
histone marks mono-, di-, and trimethylated lysine 4 of
histone H3 (H3K4me1/2/3, respectively) by Western
blot (Fig. 4). Baseline H3K4 methylation was hardly de-
tectable in all three cell lines. PS induced H3K4me1/2/3
in all three cell lines. Surprisingly, also erlotinib had a
positive effect upon methylation of this residue, particu-
larly in HCC827 and, to a lesser degree, in A549 cells.
Strikingly, the drug combination exerted a robust
synergistic effect on the expression of all three methy-
lation steps of H3K4 in both adenocarcinoma cell
lines (Fig. 4).
To investigate if there was a genomic basis for this
effect, we also checked for copy number alterations
in genes that play important roles in histone methy-
lation by removing or adding methyl groups to H3K4
(i.e. histone demethylases and methyltransferases).
We found gains for KDM4A and KDM5A (HCC827)
and of KDM5B (NCI-H460). Losses were detected of
KDM1A and KDM4A (A549) and KDM1A and
KDM2A (NCI-H460). No copy number changes could
be seen for histone methyltransferases SETD1A,
SETD1B, KMT2A/B/C/D (see Table 2). As we com-
pared these data to already published expression data
[34], we could not find a direct correlation between
copy numbers and mRNA expression (Fig. 5). These
findings suggest that differential methylation of H3K4
is not regulated by copy number alterations of
the particular demethylases and methyltransferases.
Both PS and erlotinib, alone and in combination,
could robustly induce active histone marks independ-
ently of genomic amplifications or losses of these
enzymes.
Discussion
The introduction of tyrosine kinase inhibitors antagoniz-
ing overactivated or amplified EGFR has strikingly ex-
panded the therapeutic armamentarium in non-small
cell lung cancer. However, development of resistance to
TKIs is a major clinical problem, since it occurs in al-
most all patients receiving these drugs for prolonged pe-
riods. Therefore strategies to overcome secondary
resistance to TKIs have been investigated. These include
the usage of epigenetically active agents such as HDA-
Cis. In NSCLC, this structurally diverse group of com-
pounds has been tested pre-clinically and in part also
already clinically. While single agent HDACi treatment
has only modest activity, drug combinations with
chemotherapy have been studied, with some trials being
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positive [9], others being limited by toxicity of the com-
bination [35]. A single phase II study combining erloti-
nib with the class 1 selective HDACi entinostat has
resulted in prolonged progression-free survival in
NSCLC patients harboring high E-cadherin levels, irre-
spective of the EGFR genotype [16]. The combination
of a pan-HDAC inhibitor like PS with erlotinib has so
far been investigated in a phase I trial in aerodigestive
tract tumors, which suggested that especially TKI-naïve
EGFR-mutated patients might benefit from the combin-
ation therapy [13].
In the present study, we attempted to unravel mecha-
nisms of action of the combination treatment of PS with
erlotinib in NSCLC cell lines representing different histo-
logical subtypes and different genotypes. The combination
treatment revealed variable responses: whereas prolifera-
tion of the adenocarcinoma cell lines was significantly re-
duced, the large-cell carcinoma cell line did not respond.
Table 2 Copy numbers of H3K4-specific demethylases and methyltransferases
gene KDM1A KDM2A KDM4A KDM5A KDM5B KDM5C KDM5D SETD1A SETD1B KMT2A KMT2B KMT2C KMT2D
HCC827 n n 3 3 n n n n n n n n n
A549 1 n 1 n n n n n n n n n n
NCI-H460 1 1 n n 3 n n n n n n n n
Evaluation of copy numbers of seven demethylases and six methyltransferases that specifically target lysine 4 residues of histone H3 (H3K4)
0 = complete loss, 1 = 50 % loss, n = no loss or gain, 3 = 50 % gain and 4 = 100 % gain of genomic material, relative to ploidy (all percentages are approximate
values computed with Affymetrix Genotyping Console Software)
Fig. 4 Panobinostat treatment leads to the deposition of activating histone marks which can be enhanced by erlotinib. Non-cytotoxic concentrations of
PS induced acetylation of histone H3, which is further increased by combination with erlotinib in both adenocarcinoma cell lines HCC827 and A549. Also,
the activating mono-, di- and tri-methylated H3K4 marks were at least additively induced after combination treatment in HCC827 and A549 compared
to single agent treatment with PS or erlotinib. In NCI-H460, erlotinib had no additional effect on PS-induced histone acetylation and methylation
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We also hypothesized that the inhibitory effect of erlo-
tinib on EGFR phosphorylation would be enhanced by
the HDAC inhibitor, which could indeed be demon-
strated for A549 cells and, to a much lesser degree, for
HCC827. Cooperative negative effects on downstream
signals, e.g. ERK and AKT were also seen only in these
two cell lines. Interestingly, in HCC827 erlotinib hardly
reduced phospho-EGFR levels and even upregulated
phospho-ERK expression. These findings suggest the,
already described, partial outgrowth of a TKI-insensitive
cell clone. NCI-H460 displayed no change in phospho-
AKT expression and phospho-ERK was even upregu-
lated after PS (alone and in combination with erlotinib)
treatment, underlining the insensitivity to TKIs as seen
in the proliferation experiments.
Similarly, induction of p21WAF1/CIP1 and p53 varied
broadly, with EGFR wt cell lines being overall more sen-
sitive. Here, especially NCI-H460 showed an additive ef-
fect of both drugs on p21WAF1/CIP1 expression and p53
was upregulated by PS only. This previously described
[28] PS-induced induction of p21WAF1/CIP1 and p53 was
also present in A549. In HCC827 cells erlotinib counter-
acted the impact of PS on p21WAF1/CIP1 expression; p53
was reduced by PS with no effect of erlotinib. We could
also confirm the correlation between HDAC inhibition and
p21WAF1/CIP1/p53-dependent downregulation of CHK1
[12]. Additionally, we could also detect a modest increase
in (and thus inhibition of) phospho-CHK1 after erlotinib
treatment. Taken together, this crosstalk between p21WAF1/
CIP1/p53 upregulation and CHK1 downregulation and in-
hibition provides a reasonable mechanism for the observed
growth inhibition after HDACi treatment.
HDAC inhibitors have been demonstrated to also affect
histone methylation, as we could recently show in a model
of acute myeloid leukemia [33]. Therefore we further
wished to ask whether the antiproliferative effects of PS
were associated with deposition of activating histone ly-
sine methylation marks. Indeed, we could demonstrate
that global H3K4 methylation levels, which are usually as-
sociated with accessible chromatin, were increased by PS
in all three cell lines. Unexpectedly, erlotinib as a single
agent also induced histone lysine methylation, in HCC827
and A549. Combining both drugs resulted in a synergistic
effect on H3K4 methylation (and H3 acetylation), which
strongly mirrored the antiproliferative activity of this
combination. To the best of our knowledge, a robust effect
of erlotinib upon histone methylation has not been
previously described. Possibly, induction of histone meth-
yltransferase expression or inhibition of histone demethy-
lase expression may be responsible for this effect.
Fig. 5 Expression levels of the epigenetically active enzymes of Table 2. mRNA baseline expression levels of the seven H3K4 demethylases and
five methyltransferases already depicted in Table 2. Expression levels of the three cell lines were determined by Affymetrix HG-U133A epression ar-
rays by Coldren et al. 2006 and signal intensities as reposited at the GEO database (GSE4342) were plotted. [34]
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Conclusions
Pan-HDAC inhibitors such as PS may provide a viable
option to (re) sensitize NSCLC cells, particularly of
adenocarcinoma subtype with EGFR mutations, to the
antiproliferative effects of the TKI erlotinib, warranting
further development of this approach within a clinical
phase II trial. Our study suggests that the mechanism of
action of resensitization involves reactivation of different
sets of tumor suppressor genes. We were able to show
that this is mediated by inducing an active chromatin
configuration via deposition of activating histone marks,
such as H3 acetylation and H3K4 methylation. This gen-
eral strategy may become even more relevant in the fu-
ture, since resistance to EGFR T790M-specific third
generation kinase inhibitors, like AZD9291 and Rocileti-
nib (CO-1686), already occur in the clinic which needs
to be overcome or might even be prevented [36].
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